A Conformational Escape Reaction of HIV-1 against an Allosteric Integrase Inhibitor.
Adaptor Proteins, Signal Transducing
Allosteric Regulation
/ drug effects
Anti-HIV Agents
/ pharmacology
Escape Reaction
/ drug effects
HEK293 Cells
HIV Infections
/ drug therapy
HIV Integrase
/ metabolism
HIV Integrase Inhibitors
/ chemistry
HIV-1
/ drug effects
Humans
Intercellular Signaling Peptides and Proteins
Mutation
Protein Multimerization
/ drug effects
Recombinant Proteins
Transcription Factors
Virion
/ chemistry
Virus Replication
/ drug effects
HIV-1 RNA
HIV-1 integrase
HIV-1 maturation
NCINIs
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
23
03
2020
accepted:
23
06
2020
pubmed:
3
7
2020
medline:
22
12
2020
entrez:
3
7
2020
Statut:
epublish
Résumé
HIV-1 often acquires drug-resistant mutations in spite of the benefits of antiretroviral therapy (ART). HIV-1 integrase (IN) is essential for the concerted integration of HIV-1 DNA into the host genome. IN further contributes to HIV-1 RNA binding, which is required for HIV-1 maturation. Non-catalytic-site integrase inhibitors (NCINIs) have been developed as allosteric IN inhibitors, which perform anti-HIV-1 activity by a multimodal mode of action such as inhibition of the IN-lens epithelium-derived growth factor (LEDGF)/p75 interaction in the early stage and disruption of functional IN multimerization in the late stage of HIV-1 replication. Here, we show that IN undergoes an adaptable conformational change to escape from NCINIs. We observed that NCINI-resistant HIV-1 variants have accumulated 4 amino acid mutations by passage 26 (P26) in the IN-encoding region. We employed high-performance liquid chromatography (HPLC), thermal stability assays, and X-ray crystallographic analysis to show that some amino acid mutations affect the stability and/or dimerization interface of the IN catalytic core domains (CCDs), potentially resulting in the severely decreased multimerization of full-length IN proteins (IN undermultimerization). This undermultimerized IN via NCINI-related mutations was stabilized by HIV-1 RNA and restored to the same level as that of wild-type HIV-1 in viral particles. Recombinant HIV-1 clones with IN undermultimerization propagated similarly to wild-type HIV-1. Our study revealed that HIV-1 can eventually counteract NCINI-induced IN overmultimerization by IN undermultimerization as one of the escape mechanisms. Our findings provide information on the understanding of IN multimerization with or without HIV-1 RNA and may influence the development of anti-HIV-1 strategies.
Identifiants
pubmed: 32611758
pii: JVI.00486-20
doi: 10.1128/JVI.00486-20
pmc: PMC7495394
pii:
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Intercellular Signaling Peptides and Proteins
0
PSIP1 protein, human
0
Recombinant Proteins
0
Transcription Factors
0
lens epithelium-derived growth factor
0
HIV Integrase
EC 2.7.7.-
p31 integrase protein, Human immunodeficiency virus 1
YY6481J2FF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
J Biol Chem. 2012 Jun 15;287(25):21189-203
pubmed: 22535962
Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6057-61
pubmed: 7597080
Retrovirology. 2013 Nov 21;10:144
pubmed: 24261564
Proc Natl Acad Sci U S A. 2013 May 21;110(21):8690-5
pubmed: 23610442
Lancet HIV. 2017 Jan;4(1):e31-e40
pubmed: 27863996
Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55
pubmed: 17371811
Science. 1994 Dec 23;266(5193):1981-6
pubmed: 7801124
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):22-5
pubmed: 20057045
J Biomol Screen. 2012 Jun;17(5):618-28
pubmed: 22337657
J Biol Chem. 2017 Dec 1;292(48):19814-19825
pubmed: 28972144
Retrovirology. 2014 Nov 25;11:100
pubmed: 25421939
Lancet HIV. 2017 Aug;4(8):e349-e356
pubmed: 28501495
J Biomol Screen. 2010 Oct;15(9):1099-106
pubmed: 20855563
Antimicrob Agents Chemother. 2012 Aug;56(8):4365-74
pubmed: 22664975
Clin Infect Dis. 2010 Apr 1;50(7):1041-52
pubmed: 20192725
Nat Chem Biol. 2010 Jun;6(6):442-8
pubmed: 20473303
Clin Infect Dis. 2019 Jan 7;68(2):177-187
pubmed: 30052811
J Biol Chem. 2003 Jan 3;278(1):372-81
pubmed: 12407101
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
J Biol Chem. 2014 Sep 19;289(38):26430-40
pubmed: 25118283
J Biol Chem. 2012 May 11;287(20):16801-11
pubmed: 22437836
PLoS Biol. 2016 Dec 9;14(12):e1002584
pubmed: 27935939
Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5426-30
pubmed: 8202502
Nat Protoc. 2007;2(9):2212-21
pubmed: 17853878
Retrovirology. 2013 May 30;10:57
pubmed: 23721378
J Virol Methods. 2016 Oct;236:196-206
pubmed: 27474494
Retrovirology. 2017 Nov 9;14(1):50
pubmed: 29121950
Adv Virus Res. 1999;52:411-26
pubmed: 10384245
J Virol. 2015 Oct;89(19):9765-80
pubmed: 26178982
Cell. 2016 Aug 25;166(5):1257-1268.e12
pubmed: 27565348
PLoS Pathog. 2009 Jul;5(7):e1000515
pubmed: 19609359
Science. 2017 Jan 6;355(6320):89-92
pubmed: 28059769
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
HIV AIDS (Auckl). 2018 Nov 02;10:215-224
pubmed: 30464642
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Antimicrob Agents Chemother. 2014 Jun;58(6):3233-44
pubmed: 24663024
Annu Rev Med. 2019 Jan 27;70:137-150
pubmed: 30355266
PLoS One. 2013 Sep 09;8(9):e74163
pubmed: 24040198
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
Retrovirology. 2015 Feb 12;12:16
pubmed: 25809198
PLoS Pathog. 2007 Mar;3(3):e47
pubmed: 17397262
PLoS Pathog. 2014 May 29;10(5):e1004171
pubmed: 24874515
J Virol. 2004 Dec;78(23):12735-46
pubmed: 15542626
J Org Chem. 2004 Nov 12;69(23):7822-9
pubmed: 15527257
J Biol Chem. 2013 May 31;288(22):15813-20
pubmed: 23615903